NCT01692652View on ClinicalTrials.gov

Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate

NACompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)
Interventions
DRUG

topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage

OTHER

warm compress only group

Trial Locations (1)

120-752

department of Ophthalmology, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01692652 - Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate | Biotech Hunter | Biotech Hunter